Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients

Clin Infect Dis. 1998 May;26(5):1107-10. doi: 10.1086/520280.


Disseminated infection with Penicillium marneffei is common in patients infected with human immunodeficiency virus (HIV) in Southeast Asia. Treatment with amphotericin B alone is effective but requires a prolonged hospital stay. We conducted an open-label nonrandomized study to evaluate the efficacy and safety of treatment with amphotericin B at a dosage of 0.6 mg/(kg.d) intraveneously for 2 weeks, followed by a 400-mg/d dosage of oral itraconazole for 10 weeks. Of the 74 HIV-infected patients we studied who had disseminated P. marneffei infection, diagnosed by positive fungal culture and clinical evidence of infection, 72 (97.3%) responded to the treatment. There were no serious adverse drug effects. It was concluded that the regimen was effective and safe for treatment of disseminated P. marneffei infection in HIV-infected patients.

Publication types

  • Clinical Trial

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Antifungal Agents / therapeutic use*
  • Female
  • Humans
  • Itraconazole / administration & dosage
  • Itraconazole / therapeutic use*
  • Male
  • Middle Aged
  • Mycoses / drug therapy*
  • Penicillium*
  • Thailand
  • Treatment Outcome


  • Antifungal Agents
  • Itraconazole
  • Amphotericin B